# A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

> **NCT05955105** · PHASE1,PHASE2 · RECRUITING · sponsor: **Innolake Biopharm** · enrollment: 200 (estimated)

## Conditions studied

- Head and Neck Cancer
- Cervical Cancer
- Endometrial Cancer
- Triple Negative Breast Cancer
- Ovarian Cancer
- Soft Tissue Sarcoma
- Melanoma
- Nasopharyngeal Carcinoma
- Non Small Cell Lung Cancer
- Classic Hodgkin Lymphoma

## Interventions

- **DRUG:** ILB-2109
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT05955105
- **Lead sponsor:** Innolake Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-25
- **Primary completion:** 2026-01-25
- **Final completion:** 2026-07-24
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05955105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05955105, "A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05955105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*